B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.